Navigation Links
Former InterMune CEO W. Scott Harkonen Indicted for Wire Fraud and FDA Violations
Date:3/18/2008

SAN FRANCISCO, March 18 /PRNewswire-USNewswire/ -- W. Scott Harkonen, M.D., the former CEO of InterMune Inc., was indicted on wire fraud and felony Food, Drug and Cosmetic Act charges for his role in the creation and dissemination of false and misleading information about the efficacy of InterMune's drug Actimmune (Interferon gamma-1b) as a treatment for idiopathic pulmonary fibrosis (IPF), the Justice Department announced today.

The indictment alleges that Harkonen, a medical doctor, was the chief executive officer of InterMune from February 1998 through June 30, 2003, and a member of InterMune's board of directors from February 1998 through September 2003. Under Harkonen's direction, InterMune marketed and sold Actimmune to treat IPF, a fatal disease, despite the fact that the drug was not approved by the Food and Drug Administration (FDA) as a safe and effective treatment.

According to the indictment, Harkonen promoted and caused the promotion by InterMune of Actimmune as a safe and effective treatment for IPF, despite the lack of FDA approval, in order to sell more Actimmune and to generate revenues and profits from sales of the pharmaceutical for InterMune. The cost of Actimmune for one IPF patient for one year was approximately $50,000 and the vast majority of the company's sales of Actimmune were for the unapproved, off-label use of treating IPF.

The indictment further states that Harkonen devised a scheme to induce doctors to prescribe, and patients to take, Actimmune to treat IPF. As part of that scheme to defraud, on Aug. 28, 2002, InterMune issued a press release publicly announcing the results of a clinical trial of Actimmune for the treatment of IPF. Although the clinical trial in fact failed, Harkonen caused the issuance and distribution of a false and misleading press release to portray that the results of the trial established that Actimmune helped IPF patients live longer. Specifically, the press release's headline
'/>"/>

SOURCE U.S. Department of Justice
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Cardinal Health Names Former Acting Deputy U.S. Attorney General Craig S. Morford to Chief Compliance Officer Post
2. Former Federal Reserve Chairman Paul Volcker To Join Board of Directors of Still River Systems
3. Thomas Farina, Former Pharmaceutical Company District Manager, Charged With Obstruction of Justice
4. Former Blue Cross/Blue Shield Account Manager Sentenced for Health Care Fraud Scheme, Tax Evasion
5. Lilly and Partners In Health, Brigham and Womens Hospital Team Up to Fight MDR-TB in Former Soviet Republics
6. Former Biolase CEO & EVP Launch Technology4Medicine
7. Nyer Medical Group Completes Acquisition of Minority Interest in Pharmacy Chain Subsidiary; Former Minority Shareholders Invest in Nyer Medical Group and Sign 3-Year Employment Agreements
8. OrthoSynetics(TM) Applauds SEC Suit Against Former Company Management
9. Local VA Performers Hold February 15 Benefit to Reduce $10,000 in Medical Bills for Former VCU Student Kellie Brown
10. Herley Industries Announces the Passing of Its Former President
11. Former Navy Surgeon General Is Among Three New Accomplished TriWest Advisory Board Members
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/9/2014)... heretofore hidden ways that cells are regulated, scientists at ... cancer cells more likely to metastasize. , What,s more, ... by blocking two other proteins that are normally linked ... processes could have unexpected ties. , The study, ... Nature , points to the possibility of new cancer ...
(Date:7/9/2014)... drug users in Russia might contribute to HIV ... conducted by researchers from Boston University Schools of ... Petersburg Pavlov State University, sought to discover the ... of a cohort of HIV-positive people with lifetime ... arrested by police were more likely to share ...
(Date:7/9/2014)... 8, 2014) Researchers from Montefiore Medical Center ... of Yeshiva University will present new findings at ... 12 July 17 in Copenhagen, Denmark. Data from ... prompt transition from cognitive normality to mild cognitive impairment ... Einstein Aging Study , established in 1980 to examine ...
(Date:7/9/2014)... of the most important organs in the human body. ... food properly this is its synthesis function ... this is its detoxification function. Lack of exercise ... damage the liver. The resulting diseased cells can lead ... liver failure. According to the German Liver Foundation, over ...
(Date:7/9/2014)... 2014 A study published in the scientific journal ... Robert Bonin, two researchers at Universit Laval, reveals that ... new method that involves rekindling pain so that it ... novel means to alleviate chronic pain. , The researchers ... Institut universitaire en sant mentale de Qubec (IUSMQ) were ...
Breaking Medicine News(10 mins):Health News:Protein pushes breast cancer cells to metastasize 2Health News:Protein pushes breast cancer cells to metastasize 3Health News:BU researchers relate arrests with HIV risk environment 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 2Health News:Investigators from Montefiore and Einstein to present data at 2014 Alzheimer's Association International Conference 3Health News:Telemedicine for patients with chronic liver diseases 2Health News:Telemedicine for patients with chronic liver diseases 3Health News:Discovery of a new means to erase pain 2
... , MILFORD, Mass., Sept. 1 ... the Analytical Chemistry Division of the American Chemical Society presented ... Findeis Award for Achievements by a Young Analytical Scientist. Through ... Engen has pioneered the combined use of hydrogen-deuterium ...
... SAN ANTONIO, Sept. 1 Mission Pharmacal ... a one-of-a-kind formulation that provides fast, effective relief from the ... Esrubar, L.P., and formerly distributed by Beta Dermaceuticals, Inc. ... Mission Pharmacal,s strategy to accelerate growth by continuing to expand ...
... , PLANO, Texas, Sept. 1 American Institute for ... metro-Dallas area, is using Artefill to help patients fight wrinkles for ... only FDA-approved microsphere-enhanced collagen filler for the correction of smile lines ... Raphael and Dr. Scott Harris have been using to treat patients ...
... , , SCHAUMBURG, Ill., Sept. 1 ... Veterinary Medical Association (AVMA) reveal an economic mixed bag when it ... , The survey results appear in the Journal ... 2009, article entitled, "Employment, starting salaries, and educational indebtedness of year-2009 ...
... , SAN DIEGO, Sept. 1 Volcano Corporation (Nasdaq: ... products for the diagnosis and treatment of coronary and peripheral artery disease, ... Healthcare Conference 2009 on Wednesday, September 9. , , ... a.m., Eastern Daylight Time (5 a.m., Pacific Daylight Time). , , ...
... , , , ... showed that in patients treated with LIVALO (pitavastatin), high-density ... patients attained low-density lipoprotein cholesterol (LDL-C) targets, with results ... have comparable efficacy to atorvastatin and simvastatin, as measured ...
Cached Medicine News:Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 2Health News:American Chemical Society Awards John R. Engen for Scientific Achievements 3Health News:Mission Pharmacal Acquires Dr. Smith's Diaper Ointment 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 2Health News:American Institute for Plastic Surgery is Using Artefill to Fight Patient Wrinkles 3Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 2Health News:AVMA Survey Indicates Most Starting Salaries Are Up for New Veterinarians 3Health News:Volcano Corporation Presentation at Weisel Conference to be Webcast 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 2Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 3Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 4Health News:LIVALO(R) Demonstrates Sustained, Long-Term Efficacy and Tolerability in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia 5
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital (MGH), ... AMGN ) announced today that they have launched ... new therapeutic targets and develop novel therapies for ... affects millions worldwide. The MGH-Broad-Amgen collaboration brings together ...
(Date:1/15/2014)... Texas , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ...
(Date:1/15/2014)... Ky. , Jan. 15, 2014  Manufacturers, suppliers ... must be able to protect their most important ... http://photos.prnewswire.com/prnh/20130716/CL46586LOGO ) Because of ... it steadfastly remains one of the most litigious ...
Breaking Medicine Technology:Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4Intellectual Property Insurance for Medical-related Products and Services 2
Full Handle Laseredge Implant Blade Knife, 5.2 mm straight. Blade dimension: 16.5 mm x 5.2 mm x 4.2 mm x 1.6 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel down. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Crescent Blade Knife, angled bevel up. Blade tip dimension: 12.7 mm x 2.0 mm x 3.8 mm....
Full Handle Laseredge Stab Blade Knife, 22.5 blade. Blade tip dimension: 10.7 mm x 1.8 mm x 4.2 mm....
Medicine Products: